Concepedia

Publication | Open Access

Once daily MMX mesalazine for the treatment of mild‐to‐moderate ulcerative colitis: a phase II, dose‐ranging study

DOIFull Paper Access

82

Citations

17

References

2006

Year

Geert D’Haens, Daan W. Hommes, L.G.J.B. Engels, F Baert, Laurens van der Waaij, Patrick Connor, John Ramage, Olivier Dewit, Mary Palmen, David D. Stephenson,
Alimentary Pharmacology & Therapeutics

Abstract

MMX mesalazine given as 2.4 or 4.8 g/day once daily is well tolerated and effective for the treatment of mild-to-moderately active ulcerative colitis.

References

YearCitations

Page 1